Sensus Healthcare resumed with a Buy at Roth MKM

Roth MKM resumed coverage of Sensus Healthcare with a Buy rating and $10 price target. The company’s proprietary superficial radiation therapy is an effective treatment for non-melanoma skin cancer and keloids, with better cosmetic outcomes and comparable, if not better, cure rates compared to traditional Mohs surgery, the analyst tells investors in a research note. Sensus’s strong rebound in capital equipment purchases in FY24 – up 116% from last year in Q1 – and implementation of a new revenue-sharing program will enhance the recurring revenue stream beginning in the second half of this year, with a greater impact in 2025, the firm added.